| Background: Tumor is one of the main reasons for human life and healththreat. In our country, obstetrics and gynecology tumor has become an importantfactor affecting the majority of women’s quality of life and survival period, andendometrial carcinoma is one of the three kinds of therioma in female genital tract,accounting for7%of all female therioma, and accounting for20%-30%of femalegenital tract therioma. The endometrial adenocarcinoma is accounted for about80%~90%in endometrial carcinoma. The pathogenesis of endometrial carcinomais still unclear, and the possible cause is the occurrence of endometrial hyperplasia,even cancer by the long-term effects of estrogen. Early detection and earlytreatment is an important principle in the treatment of cancer. Follistatin (FS), alsoknown as activin-binding protein or follicle stimulating hormone (FSH) inhibitedthe protein, is a single-chain glycoprotein, which inhibits the secretion of FSH, andit has a broad tissue distribution and the biological activity. Activin (ACT) is atransforming growth factor-β (TGF-β) superfamily globulin member, which hasfive subunits forms of β A, β B, β C, β D, β E according to the different containingsubunit, which has divided into three molecular forms of activin A, activin B,activin AB. Activin A (activin A) is a homodimer with two protein composed of A,A two subunits. Most of the present research is Activin A. Activin A and FS usuallyis co-expression, which has a broad tissue distribution and participates inadjustment in many kinds of physiologic functions and pathological features.Activin A-FS system has gradually become a new research hotspot in the field ofmedicine. The exploration of the relationship between its expression imbalance andthe occurrence of tumor, and the relationship between ActivinA-FS and ovariancancer, breast cancer, liver cancer has gradually been confirmed. In recent years, some studies have found that FS, Activin A are expressed in many tumor tissues ofpatients with endometrial carcinoma, and Activin A increased expression in serum,and there maybe is a close relationship between expression imbalance of ActivinA-FS and endometrial carcinoma occurrence, development。Objective：In this paper, using the method of immunohistochemical stainingdetects the distribution of FS, Activin A in endometrioid adenocarcinoma tissue.Using the double antibody sandwich ELISA method measures FS, Activin A proteinlevels in peripheral blood of healthy adults and patients with endometrialadenocarcinoma of, and measure changes of FS, Activin A protein levels inendometrioid adenocarcinoma patients’ tissues with different pathological stagingand differentiation degree. It investigates the incidence and developmentrelationship between the two kinds of protein in endometrial adenocarcinoma, andprovides the theoretical support for the early diagnosis and prognosis evaluation.Methods: The choice of samples of healthy adult serum and endometrioidadenocarcinoma serum and tissue in China-Japan Union Hospital of Jilin Universityin2010-2012for3years were124cases, including serum in50healthy adults,60cases of endometrioid adenocarcinoma and9cases of endometrioid adenocarcinomaserum and5cases of normal endometrium. There are4cases of high differentiationadenocarcinoma serum (G1),34cases of adenocarcinoma serum (G2) and22casesof poorly differentiated adenocarcinoma serum (G3). According operation andpathology stage standard drafted by the International Federation of gynecology andObstetrics (FIGO), including stage I46cases of endometrial adenocarcinoma serum,II10cases of endometrioid adenocarcinoma serum, stage III4cases ofendometrioid adenocarcinoma serum. Selected9cases of tumor tissue from60patients were used for immunohistochemical staining. All peripheral blood samplesafter centrifugation separation of serum, put in-80℃refrigerator, to be detected.Have9cases of adenocarcinoma tissue, in which every3cases in differentoperation pathologic staging and histopathology grade. The tumor tissue after theoperation, formalin fixed, paraffin embedded, is continuously sliced by the Leica(RM2125) paraffin slicing machine, which thickness of about4micron, used forimmunohistochemistry. Statistical analysis of data is applicated by SPSS19.0statistical software for. Result：1. Immunohistochemical staining detection found FS protein expression inendometrial adenocarcinoma tissue, but no obvious difference of staining intensitywhen compared with normal endometrial tissue.2. ELISA detection found that the content of FS was without significantdifference in peripheral blood circulation of patients with endometrialadenocarcinoma than that in the healthy control group, P>0.05.3. Immunohistochemical detection of Activin A protein expression in tumortissue, showed that Activin A in endometrial carcinoma tissues showed strongpositive staining, the staining intensity was significantly higher than that in normalendometrium.4. The content of Activin A in peripheral blood circulation of patients withendometrial adenocarcinoma detected by ELISA was significantly higher than thatin the healthy control group, P<0.01.5. Different levels of Activin A protein in peripheral blood circulation ofpatients with endometrial adenocarcinoma for different pathological stages anddifferent degrees of differentiation, results showed that the Activin A protein levelsin patients with the late pathological stage and the low degree of differentiation isobviously increased, P<0.05.6. FS and Activin A expression in endometrioid adenocarcinoma was positivecorrelation, r=0.632, P<0.01.Conclusion:1. The high level expression of Activin A may promote occurrence anddevelopment of endometrial adenocarcinoma.2. Endometrial adenocarcinoma may be associated with the Activin A-FSsystem imbalance. Activin A is an important pathogenic factor of this disease, andthe high level expression of Activin A may indicate the high level malignant degreeof endometrioid adenocarcinoma and the bad prognosis.3. The detection of Activin A expression in the peripheral blood circulation ofpatients with endometrial adenocarcinoma may become the effective serological clinical indicators.4. The expression of FS and Activin A in the serum of patients withendometrioid adenocarcinoma may be positive correlation. The combined detectionto their two content may be of some help to the further study on the diagnosis andprognosis of endometrioid adenocarcinoma. |
PDF Full Text Request